Last reviewed 2026-04-23 · How we verify

AK129

Akeso · Phase 1 active Small molecule

At a glance

Generic name	AK129
Sponsor	Akeso
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

AK129 Combination Therapy for Advanced Solid Tumors (PHASE1, PHASE2)
A Study of AK129 in Patients With Advanced Malignant Tumors (PHASE1)
A Study of AK129 With or Without AK117 in PD(L)1-refractory Classic Hodgkin Lymphoma (PHASE1, PHASE2)
A Study of Anti-PD-1 and LAG-3 Bispecific Antibody(AK129) Combined With Chemotherapy With or Without Cadonilimab in the First-line Treatment of Unresectable Locally Advanced or Metastatic G/ GEJ Adenocarcinoma (PHASE1, PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

AK129 CI brief — competitive landscape report
AK129 updates RSS · CI watch RSS
Akeso portfolio CI